Get the Stockscreener App
3.49
6.08%
0.20
After Hours:
3.48
-0.01
-0.29%
Cabaletta Bio Inc stock is traded at $3.49, with a volume of 8.42M.
It is up +6.08% in the last 24 hours and up +9.75% over the past month.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$3.29
Open:
$3.33
24h Volume:
8.42M
Relative Volume:
2.82
Market Cap:
$335.97M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-2.1024
EPS:
-1.66
Net Cash Flow:
$-54.24M
1W Performance:
+11.50%
1M Performance:
+9.75%
6M Performance:
+119.50%
1Y Performance:
+76.26%
1-Day Range:
$3.31
$3.78
1-Week Range:
$2.79
$3.78
52-Week Range:
$0.9857
$3.78
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
3.49 | 316.71M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Resumed | Jefferies | Buy |
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
Millennium Management LLC's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
Short Covering: Will Cabaletta Bio Inc announce a stock split2025 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
Aug EndMonth: What drives SATLWs stock price2025 Market Sentiment & Stock Market Timing Techniques - baoquankhu1.vn
Dividend Watch: Is PECO stock a falling knife or bargain buyRisk Management & Growth Oriented Trade Recommendations - baoquankhu1.vn
Here’s why Jacob Funds established a position in Cabaletta Bio (CABA) - MSN
Market Rankings: Is Cabaletta Bio Inc stock trending bullishJuly 2025 Analyst Calls & High Accuracy Swing Trade Signals - baoquankhu1.vn
Millennium Group (CABA) jointly reports 5.3% holding of 5.13M shares - Stock Titan
Aug Shorts: Does Cabaletta Bio Inc have strong EBITDA marginsJuly 2025 Update & Accurate Buy Signal Notifications - baoquankhu1.vn
Here’s Why Jacob Funds Established a Position in Cabaletta Bio (CABA) - Insider Monkey
What are Cabaletta Bio Inc.’s recent SEC filings showingPortfolio Update Summary & Daily Risk Controlled Trade Plans - mfd.ru
Best Swing Trade Stocks Right Now • Updated Daily - Benzinga
Pharma News: Why retail investors favor Cabaletta Bio Inc. stock2025 Historical Comparison & Fast Entry High Yield Tips - mfd.ru
Cabaletta Bio Kicks Off Pivotal Myositis Trial, Touts Automated CAR-T Manufacturing Path to 2027 BLA - MarketBeat
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? - Nasdaq
Aug Drivers: Is Cabaletta Bio Inc stock a smart retirement pickJuly 2025 Recap & Fast Moving Market Watchlists - baoquankhu1.vn
CABA News Today | Why did Cabaletta Bio stock go up today? - MarketBeat
Cabaletta Bio Takes Spotlight at Guggenheim Summit as Autoimmune Bet Advances - MyChesCo
Update Recap: Is Cabaletta Bio Inc stock overvalued or fairly priced2025 Macro Impact & AI Powered Market Entry Strategies - baoquankhu1.vn
Trend Review: Is Cabaletta Bio Inc stock overvalued or fairly pricedJuly 2025 Technicals & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Globe and Mail
Cabaletta Bio to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - Quiver Quantitative
Risk Off: What is Cabaletta Bio Incs P E ratio telling usJuly 2025 PostEarnings & Weekly High Return Stock Forecasts - baoquankhu1.vn
Swing Trade: Can Cabaletta Bio Inc deliver consistent dividendsQuarterly Earnings Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
US Market Wrap: Can Cabaletta Bio Inc disrupt its industryJuly 2025 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Highs Report: Will Tucows Inc outperform its industry peersMarket Activity Recap & Fast Moving Stock Trade Plans - baoquankhu1.vn
What makes Cabaletta Bio, Inc. (CABA) a strong momentum stock: Buy now? - MSN
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Guggenheim reiterates Buy rating on Cabaletta Bio stock, citing commercial plan - Investing.com Nigeria
Cabaletta Bio: Do You Buy With The Insiders? (NASDAQ:CABA) - Seeking Alpha
Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Largest borrow rate increases among liquid names - TipRanks
Assessing Cabaletta Bio (CABA) Valuation After Insider Buying And FDA Clearance For Automated CAR T Manufacturing - Yahoo Finance
Stock Analysis: Does Cabaletta Bio Inc have pricing powerWeekly Trend Recap & Daily Growth Stock Investment Tips - baoquankhu1.vn
Strategic Partnerships Propel Cabaletta Bio Forward - StocksToTrade
Cabaletta Bio Unveils Strategic Plans Amid Price Target Revision - timothysykes.com
Cabaletta Bio Aims High with Strategic Initiatives for 2026 - StocksToTrade
Steven Nichtberger Bought 3.3% More Shares In Cabaletta Bio - Sahm
Returns Recap: Is Cabaletta Bio Inc stock trending bullishGap Down & Community Verified Trade Signals - baoquankhu1.vn
Cabaletta Bio Unveils Strategic Plans Amid Financial Forecast Changes - StocksToTrade
Cabaletta Bio Stock (CABA) Opinions on Insider Buying and Clinical Updates - Quiver Quantitative
Cabaletta targets 2027 FDA filing as autoimmune CAR-T push accelerates - MSN
Cabaletta Bio Advances Rese-cel Toward Pivotal Milestones, Expands Autoimmune Cell Therapy Pipeline - RTTNews
Why Cabaletta Bio (CABA) Is Up 41.3% After FDA Clears Automated CAR T Manufacturing Platforms - Yahoo Finance
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences - MSN
Cabaletta Bio Sees Unusually Large Options Volume (NASDAQ:CABA) - MarketBeat
Cabaletta Bio (CABA) Shares Surge 11% After Insider Buying - GuruFocus
Cabaletta Bio stock jumps 11% premarket after insider buying cluster hits the tape - TechStock²
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):